Advertisement
Emerging research and innovation shared
Choosing which sessions to attend at ASCO can be overwhelming, given the number of high-value research reports being shared. In this article, we’ve curated the top 10 presentations you don’t want to miss at this year’s event.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
1:54-2:06 PM EDT, Monday, June 5
Abstract# 4505
5:24-5:36 PM EDT, Monday, June 5
Abstract# 10505
10:24-10:36 AM EDT, Monday, June 5
Abstract# 6005
5:12-5:24 PM EDT, Monday, June 5
Abstract# 9504
12:30-2:00 PM EDT, Monday, June 5
Abstract# 7010, Poster bd# 140
Monday, June 5
12:30-2:00 PM EDT
Abstract# 7016, Poster bd# 146
5:30-7:00PM EDT, Monday, June 5
Abstract# 6017, Poster bd# 9
Advertisement
5:30-7:00 PM EDT, Saturday, June 3
Abstract# 3510
2:15-5:15 PM EDT, Saturday, June 3
Abstract# 2060, Poster bd# 417
2:15-5:15 PM EDT, Saturday, June 3
Abstract# 6603, Poster bd# 95
Advertisement
Advertisement
Polygenic risk score could help predict who will develop this aggressive breast cancer
Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’
Extent of baseline burden impacts progression-free and overall survival
Further study warranted to better understand the clinical implications of these findings
Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel
Oral anticoagulants may be beneficial but need to be balanced against bleeding risks
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels